title: Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment.
abstract: BACKGROUND
  The effects of pan-peroxisome proliferator-activated receptor (PPAR) ligand bezafibrate on N-terminal pro-B type natriuretic peptide (ProBNP) level in patients with coronary artery disease (CAD) is unknown. The current study aimed to investigate the long-term effects of bezafibrate on ProBNP level in patients with pre-existing CAD and advanced functional capacity impairment.
  
  
  METHODS
  Metabolic and inflammatory parameters were analyzed from stored frozen serum samples obtained from 108 patients enrolled in the Bezafibrate Infarction Prevention (BIP) Study. They presented with New York Heart Association (NYHA) functional class III, comprising 58 patients in the bezafibrate group and 50 in the placebo groups, and completed a 2-year prospective, double-blind, placebo-controlled follow-up.
  
  
  RESULTS
  During follow-up ProBNP level did not change significantly in the placebo group, whereas it increased slightly in the bezafibrate group, which was older and with lower baseline ProBNP values. No significant differences between the groups were found for ProBNP levels after 2 year of follow-up. Analysis-of-covariance (ANCOVA) -taking into account age and baseline ProBNP level- showed that bezafibrate was not associated with longitudinal ProBNP changes during the follow-up period (p = 0.3).
  
  
  CONCLUSIONS
  Long-term treatment by bezafibrate was not associated with longitudinal ProBNP changes in patients with pre-existing CAD and advanced functional capacity impairment.
authors.affiliation: Department of Cardiovascular and Renal Medicine, Saga University Faculty of Medicine, Saga, Japan. node@cc.saga-u.ac.jp
authors.forename: Koichi
authors.initials: K
authors.lastname: Node
authors.forename: Teruo
authors.initials: T
authors.lastname: Inoue
authors.forename: Valentin
authors.initials: V
authors.lastname: Boyko
authors.forename: Ilan
authors.initials: I
authors.lastname: Goldberg
authors.forename: Enrique Z
authors.initials: EZ
authors.lastname: Fisman
authors.forename: Yehuda
authors.initials: Y
authors.lastname: Adler
authors.forename: Ehud
authors.initials: E
authors.lastname: Schwammenthal
authors.forename: Zipora
authors.initials: Z
authors.lastname: Matas
authors.forename: Solomon
authors.initials: S
authors.lastname: Behar
authors.forename: Alexander
authors.initials: A
authors.lastname: Tenenbaum
mesh_terms: D000368:Aged; D001629:Bezafibrate / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D003324:Coronary Artery Disease / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000097:blood* / Q000209:etiology; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D047495:PPAR gamma / Q000819:agonists / Q000502:physiology; D010446:Peptide Fragments / Q000097:blood*; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists*; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D012720:Severity of Illness Index
chemical_list: D000960:Hypolipidemic Agents; D047495:PPAR gamma; D010446:Peptide Fragments; D047492:Peroxisome Proliferator-Activated Receptors; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D001629:Bezafibrate